Trial · NCT05288062
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
NCT05288062, Phase 2, Terminated, Mayo Clinic; results first posted 2025-08-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma. Trials, record NCT05288062. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05288062
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
- NCT number
- NCT05288062
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
- Interventions
- Bone Marrow Biopsy, Dexamethasone, Lenalidomide, Pomalidomide
- First posted
- 2022-03-18
- Last updated
- 2026-09-28
- Results first posted
- 2025-08-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rates (RR) at First Assessment | 21 days | RR is defined as a binary variable. A success will be defined as patient who achieve a response of a partial response (PR) or better using the International Myeloma Working Group (IMWG) criteria. Biomarkers of interest will be identified and categorized into clinically relevant groups (e.g. positive vs. negative) by evaluating baseline and post treatment (after cycle one) biospecimens. RR will be estimated within each biomarker. Each cohort (A-D) will be evaluated separately and independently. |
| Secondary | Response Rates (RR) Among African American (AA) and White Patients | Up to completion of 1 cycle of treatment (21 days) | Pearson's Chi-square (or Fischer Exact) test and 95% confidence intervals will be estimated to compare patients of different races descriptively. |
| Secondary | Depth of Hematological Responses | 6 months | Correlation between the depth of hematological responses and biomarkers will be estimated. Logistic regressions and chi square (or Fischer exact) testing will be utilized. |
| Other | Predictive Biomarkers | Up to 6 months | Biomarkers and RR will be analyzed using logistic regressions to identify predictive biomarkers. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rates (RR) at First Assessment | 21 days | Only patients that completed the study were included in analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Predictive Biomarkers | Up to 6 months | |||
| SECONDARY | Response Rates (RR) Among African American (AA) and White Patients | Up to completion of 1 cycle of treatment (21 days) | |||
| SECONDARY | Depth of Hematological Responses | Up to 6 months |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rates (RR) at First Assessment | Cohort B (Lenalidomide, Dexamethasone) | 1 | Participants | ||
| Response Rates (RR) at First Assessment | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 4 | Participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort A (Lenalidomide, Dexamethasone) | 0 | |
| Overall Study | STARTED | Cohort B (Lenalidomide, Dexamethasone) | 5 | |
| Overall Study | STARTED | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 12 | |
| Overall Study | STARTED | Cohort D (Lenalidomide, Dexamethasone, Pomalidomide) | 0 | |
| Overall Study | COMPLETED | Cohort A (Lenalidomide, Dexamethasone) | 0 | |
| Overall Study | COMPLETED | Cohort B (Lenalidomide, Dexamethasone) | 5 | |
| Overall Study | COMPLETED | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 10 | |
| Overall Study | COMPLETED | Cohort D (Lenalidomide, Dexamethasone, Pomalidomide) | 0 | |
| Overall Study | NOT COMPLETED | Cohort A (Lenalidomide, Dexamethasone) | 0 | |
| Overall Study | NOT COMPLETED | Cohort B (Lenalidomide, Dexamethasone) | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events60
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Cohort B (Lenalidomide, Dexamethasone) | 2 | 5 | 2 |
| other | Anemia | Blood and lymphatic system disorders | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 2 | 11 | 2 |
| other | Sinus tachycardia | Cardiac disorders | Cohort B (Lenalidomide, Dexamethasone) | 1 | 5 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 0 | 11 | 0 |
| other | Eye pain | Eye disorders | Cohort B (Lenalidomide, Dexamethasone) | 1 | 5 | 1 |
| other | Eye pain | Eye disorders | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 0 | 11 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Cohort B (Lenalidomide, Dexamethasone) | 0 | 5 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 1 | 11 | 1 |
| other | Constipation | Gastrointestinal disorders | Cohort B (Lenalidomide, Dexamethasone) | 2 | 5 | 2 |
| other | Constipation | Gastrointestinal disorders | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 1 | 11 | 1 |
1 to 10 of 60Source ClinicalTrials.gov
See all 60 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort B (Lenalidomide, Dexamethasone) | 0 | 5 |
| Total, all-cause mortality | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 0 | 11 |
| Total, other adverse events | Cohort B (Lenalidomide, Dexamethasone) | 3 | 5 |
| Total, other adverse events | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 10 | 11 |
| Total, serious adverse events | Cohort B (Lenalidomide, Dexamethasone) | 0 | 5 |
| Total, serious adverse events | Cohort C (Lenalidomide, Dexamethasone, Pomalidomide) | 2 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | WILLMAN, CHERYL LYNN | MAYO CLINIC ROCHESTER | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cohort B (Lenalidomide, Dexamethasone) vs Cohort C (Lenalidomide, Dexamethasone, Pomalidomide): deaths from any cause | Trial comparisons |
| Cohort B (Lenalidomide, Dexamethasone) vs Cohort C (Lenalidomide, Dexamethasone, Pomalidomide): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05288062
GET https://conductscience.org/api/trials/v1/NCT05288062/events?page=2